Message

From: Tegeris, John (OS/ASPR/BARDA) (CTR) [john.tegeris@hhs.gov]
Sent: 5/17/2017 1:49:26 PM
To: Bright, Rick (OS/ASPR/BARDA) [Rick.Bright@hhs.gov]; Disbrow, Gary (OS/ASPR/BARDA) [Gary.Disbrow@hhs.gov]; Schafer, Julie (OS/ASPR/BARDA) [Julie.Schafer@hhs.gov]; Maher, Carmen (FDA/OC) [Carmen.Maher@fda.hhs.gov]; Sadove, Elizabeth (FDA/OC) [Elizabeth.Sadove@fda.hhs.gov]; Ross, Jennifer (FDA/OC) [Jennifer.Ross@fda.hhs.gov]; Nalubola, Ritu (FDA/OC) [Ritu.Nalubola@fda.hhs.gov]; Flamm, Eric (FDA/OC) [Eric.Flamm@fda.hhs.gov]; Zborowsky, Ashley (FDA/OC) [Ashley.Zborowsky@fda.hhs.gov]; Epstein, Laura (FDA/CVM) [Laura.Epstein@fda.hhs.gov]; Hartman, Mark [Hartman.Mark@epa.gov]; McNally, Robert [Mcnally.Robert@epa.gov]; Mendelsohn, Mike [Mendelsohn.Mike@epa.gov]; Milewski, Elizabeth [Milewski.Elizabeth@epa.gov]; Wozniak, Chris [wozniak.chris@epa.gov]; Jennings, Susan [Jennings.Susan@epa.gov]; Layne, Arnold [Layne.Arnold@epa.gov]; Rosenblatt, Daniel [Rosenblatt.Dan@epa.gov]; Petersen, Lyle (CDC/OID/NCEZID) [lxp2@cdc.gov]; Beard, Charles (Ben) (CDC/OID/NCEZID) [cbb0@cdc.gov]; Koonin, Lisa (CDC/OID/NCIRD) [lmk1@cdc.gov]; Kovacs, Gerald (OS/ASPR/BARDA) (CTR) [Gerald.Kovacs@hhs.gov]; Seals, Jonathan (OS/ASPR/BARDA) [jonathan.seals@hhs.gov]; Craven, Mark (OS/ASPR/BARDA) [Mark.Craven@hhs.gov]; Knight, Antoinette (OS/ASPR/BARDA) [Antoinette.Knight@hhs.gov]; Costero-Saint Denis, Adriana (NIH/NIAID) [E] [acostero@niaid.nih.gov]; Leissa, Brad G (FDA/CDER) [Brad.Leissa@fda.hhs.gov]; Lueptow, Rebekka (HHS/ASPR/BARDA) [Rebekka.Lueptow@hhs.gov]; Wolf, Laura (OS/ASPR/OEM) [Laura.Wolf@hhs.gov]; Curren, Stephen (OS/ASPR/OEM) [Stephen.Curren@hhs.gov]; Erlandson, Karl (OS/ASPR) [Karl.Erlandson@hhs.gov]; JBobo@intrexon.com; hutchinsont@gtlaw.com; Simon Warner [Simon.Warner@oxitec.com]; Little, James (OS/ASPR/BARDA) [James.Little@hhs.gov]; Tegeris, John (OS/ASPR/BARDA) (CTR) [john.tegeris@hhs.gov]
CC: Fensom, Meredith [MFensom@intrexon.com]; Leahy, John [Leahy.John@epa.gov]; Shimkin, Martha [Shimkin.Martha@epa.gov]
Subject: Oxitec Slide Deck Attached: Interagency Meeting with Oxitec/Intrexon Group; Wed May 17, 10am-12pm ET
Attachments: Regulatory overview US 5-17-2017.pptx

Hi All,

We are very much looking forward to our interagency meeting with the Oxitec group this morning and to the opportunity to meet new colleagues across agencies. We greatly appreciate the time everyone has set aside to participate in the open/interactive dialogue on tap for today. The Oxitec group sent along the attached slide presentation this morning to share with the interagency team, to use primarily as a reference to help guide the discussion. We will likely not need the full two hours for our meeting, but will address that on the fly as the meeting unfolds. Many thanks!

Best,
John

Ex. 6 - Personal Privacy